Navigation Links
HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
Date:3/7/2012

An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). Scientists at Emory University and GeoVax Labs, Inc. developed a vaccine that has protected nonhuman primates against multiple exposures to simian immunodeficiency virus (SIV) given in three clusters over more than three years. SIV is the nonhuman primate version of HIV.

Harriet L. Robinson, PhD, chief scientific officer at GeoVax Labs, Inc., and former director of the division of microbiology and immunology at Yerkes National Primate Research Center, has been leading the research team with Rama Rao Amara, PhD, associate professor of microbiology and immunology, Yerkes National Primate Research Center and the Emory Vaccine Center.

The research was presented Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

The vaccine regimen included a DNA prime vaccine that co-expressed HIV proteins and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a normal protein that promotes the initiation of immune responses and thus enhances the ability of the vaccine to elicit blocking antibodies for the SIV virus before it enters cells.

Vaccination consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. The booster vaccine was MVA, an attenuated poxvirus expressing HIV proteins. Six months after the last vaccination, both vaccinated and unvaccinated animals were exposed to SIV through 12 weekly exposures, resulting in an 87 percent per exposure efficacy and 70 percent overall protection. Over the next two years uninfected animals were exposed multiple times in two more series, resulting in an 82 percent per exposure efficacy during the second series and an 84 percent per exposure efficacy during the third series.

"Repeated challenges in animals are used to mimic sexual transmission," says Robinson. "The hope is that the results in the nonhuman primate models will translate into vaccine-induced prevention in humans."

"It is impressive to note that protection could be observed against both neutralization sensitive and neutralization resistant viruses," says Amara.

Neutralization is the process by which some antibodies can block virus infection.

A first generation GeoVax DNA/MVA vaccine that does not co-express GM-CSF has shown excellent safety and reproducible vaccine responses in Phase 1 and 2a clinical trials in more than 400 uninfected people. These trials, supported and conducted by the National Institutes of Health HIV Vaccine Trials Network, have set the stage for the second-generation GM-CSF co-expressing vaccine to move from its initial Phase 1 safety testing slated to start in March of this year to a Phase 2b efficacy trial in participants who are at high risk of exposure to HIV. The vaccine is designed for a version of the virus prevalent in the Americas.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Headaches May Plague Many With HIV/AIDS
2. Children with HIV/AIDS falling through the cracks of treatment scale-up efforts
3. Despite Advances, HIV/AIDS Still Takes Heavy Emotional Toll
4. Advocates Push for Greater Awareness of HIV/AIDS
5. Preventing HIV/AIDS 1 SMS at a time
6. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
7. Boston Medical Center awarded $1M to expand HIV/AIDS patient care services
8. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
9. International AIDS Society urges world leaders at UN General Assembly High-Level Meeting on HIV/AIDS to integrate a fourth pillar -- HIV cure research -- into the global response to the epidemic
10. Key goals for building on 30 years of HIV/AIDS research
11. Preventing the spread of HIV/AIDS with humanized BLT mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China – ... ... (PRWEB) January 18, 2017 -- Global public health organization ... reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water ... drinking water treatment units. This certification verifies that MicroCeramics’ NanoNose ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
(Date:1/18/2017)... ... 2017 , ... PrideStaff, a national, franchised staffing organization ... Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with kathy ... leaders from across the globe, provides viewers an opportunity to find solutions to ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park Agencies Insurance ... services to families and business owners in the greater Kansas City area, is ... developmental disabilities. , The Lakemary Center is a comprehensive educational resource center that ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is an esteemed dentist ... His modern dental practice has two convenient office locations in Alexandria and Arlington, Virginia. ... Dentist for the Alexandria area. This award confirms the fact that Dr. Qureshi’s ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , January 18, 2017 According to a new report ... Application: Global Opportunity Analysis and Industry Forecast, 2014 - 2022," the global polyphenol ... $1,127 million by 2022, growing at a CAGR of 8.26% from 2016 to ... of revenue. Continue Reading ... ...
(Date:1/18/2017)... GREENWOOD VILLAGE, Colo. , Jan. 18, 2017 /PRNewswire/ ... an independent chain of pharmacies based in ... Safe Rx™ Locking Prescription Vials (LPVs) in selected Good Day ... abuse now have a cost-effective alternative for secure storage," ... Safe Rx.  "For less than the price of a ...
(Date:1/18/2017)... , Jan. 18, 2017   Seno Medical ... of diagnosing breast cancer through the development of an ... Steve Miller as SVP of Engineering. Mr. ... Realization at FUJIFILM SonoSite, with headquarters in ... majority of his 30-year career to the development of ...
Breaking Medicine Technology: